Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT – Get Free Report) have received a consensus recommendation of “Buy” from the six analysts that are presently covering the stock, MarketBeat reports. Six investment analysts have rated the stock with a buy rating. The average twelve-month target price among brokerages that have issued a report on the stock […]
Capital One Financial began coverage on shares of EyePoint Pharmaceuticals (NASDAQ:EYPT – Free Report) in a research report released on Monday morning, Benzinga reports. The firm issued an overweight rating and a $44.00 target price on the stock. Capital One Financial also issued estimates for EyePoint Pharmaceuticals’ Q4 2023 earnings at ($0.76) EPS, FY2023 earnings […]
EyePoint Pharmaceuticals (NASDAQ:EYPT – Free Report) had its price objective hoisted by HC Wainwright from $25.00 to $35.00 in a report issued on Tuesday, Benzinga reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for EyePoint Pharmaceuticals’ Q4 2023 earnings at ($0.43) EPS, FY2023 earnings at ($1.92) EPS, Q1 […]
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT – Get Free Report) has been assigned a consensus recommendation of “Buy” from the five ratings firms that are presently covering the stock, MarketBeat reports. Five research analysts have rated the stock with a buy rating. The average 12-month price objective among brokers that have issued ratings on the stock in […]
Cantor Fitzgerald reiterated their overweight rating on shares of EyePoint Pharmaceuticals (NASDAQ:EYPT – Free Report) in a research report report published on Thursday morning, Benzinga reports. Cantor Fitzgerald currently has a $31.00 target price on the stock. A number of other research analysts have also weighed in on EYPT. StockNews.com initiated coverage on shares of […]